394 results about "Eye drops solution" patented technology

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The invention discloses a liquid chromatography detection method and system for eye drops, and relates to the technical field of chromatographic detection.The liquid chromatography detection method comprises the steps that liquid chromatography analysis is conducted to obtain an original chromatographic signal; performing adaptive baseline correction on the original chromatographic signal to obtain a corrected chromatographic signal, synchronizing the corrected chromatographic signal to a chromatographic peak identification analysis model for identification to obtain a plurality of chromatographic peaks including principal component peaks and specific impurity peaks, and performing calculation to obtain a first integral area of the principal component peaks and a second integral area of the specific impurity peaks; the preset correction factor is combined with the first integral area and the second integral area to automatically carry out quantitative calculation on the eye drops, and a liquid chromatogram detection report of the eye drops is generated. The technical problems that in the prior art, main component peak and impurity peak recognition and quantification depend on manual processing in the eye drop liquid chromatogram detection process, and accuracy and consistency are insufficient are solved, and the technical effects that the accuracy and automation level of eye drop liquid chromatogram detection are improved, and it is guaranteed that main component and impurity quantification results are stable and consistent are achieved.

The invention relates to the technical field of biological medicine, in particular to eye drops containing recombinant protein as well as a preparation method and application of the eye drops. Comprising the following components: 0.01%-1% of recombinant human TFF3 protein, 0.1%-1% of an osmotic pressure regulator, 0.08%-2% of a pH regulator, 0.05%-0.15% of a thickening agent, 0.01%-0.1% of a surfactant, 0.01%-0.1% of a protective agent and the balance of water for injection, the traditional Chinese medicine composition can be used for treating the xerophthalmia, can promote wound healing and cell migration, has the effects of inhibiting inflammation and cell apoptosis, and can act on a plurality of target spots at the same time, so that the tear film stability is improved, ocular surface inflammation is inhibited, the vicious circle of the xerophthalmia is broken, and the xerophthalmia is treated more comprehensively and effectively; the problems that in the prior art, xerophthalmia medicine targets are single, and xerophthalmia cannot be comprehensively and effectively treated are solved.

The invention discloses a preparation method of eye drops for treating glaucoma, cataract and vitreous opacification. The eye drops comprise the following components: berberine, N-acetyl carnosine and lycium barbarum polysaccharide. The specific formula comprises the following components: 0.1%-0.5% of berberine, 1%-3% of N-acetyl carnosine and 0.5%-2% of lycium barbarum polysaccharide. The invention belongs to the technical field of ophthalmic pharmaceutical preparations, and solves the problems that in the prior art, glaucoma, cataract and vitreous opacity generally need to be separately taken, the research on compound preparations is less, and the components possibly interact with one another.

According to the nitrogen hydrochloride # imgabs0 # stine eye drops for treating allergic conjunctivitis and the preparation method of the nitrogen hydrochloride # imgabs0 # stine eye drops, the prepared eye drops can interact with the mucous layer on the surface of keratoconjunctiva by selecting specific solid lipid and a surfactant and controlling the dosage of the solid lipid and the surfactant; the retention capacity of the medicine in front of the cornea is prolonged, so that the medicine has good targeting property, the continuous release of the medicine is realized, the medication frequency can be reduced, the toxic and side effects of the medicine are reduced, the bioavailability is improved, the medication compliance of a patient is enhanced, and in the preparation and long-term storage processes, the medicine has better stability, and is suitable for popularization and application. Therefore, the problems of excessive drug due to multiple administration and poor stability of the active component nitrogen hydrochloride # imgabs1 # stine are solved.

The invention relates to a near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system and a preparation method and application thereof, a mesoporous silicon coated up-conversion nano-carrier and an efficient photosensitizer are compounded to form a photo-response core unit, and then the photo-response core unit is intelligently integrated with photo-curing hydrogel to form the near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system. The general problem of aggregation and quenching of photosensitive molecules is relieved by utilizing the unique space confinement effect of the mesoporous structure, the ICG photo-thermal efficiency and photodynamic performance are enhanced, under precise excitation of a near-infrared light source, the system can activate a photo-crosslinking reaction through an up-conversion luminescence process, in-situ conversion from a liquid eye drop preparation to a stable gel state is achieved, and the stability of the eye drop preparation is improved. A lasting drug reservoir is formed on the surface of the cornea; synchronously excited photodynamic and photo-thermal dual-mode treatment generates a remarkable synergistic antibacterial effect, and shows an excellent removal capability on pathogens including highly drug-resistant bacteria; meanwhile, an ideal microenvironment is created for tissue repair through high biocompatibility and a stable mechanical matrix, and integrity recovery of cornea structures and functions is promoted.

The invention discloses eye drops containing L-ergothioneine and a preparation method of the eye drops. The eye drops are prepared from the following components in parts by weight: 0.0015 to 15 parts of L-ergothioneine, 0.001 to 0.01 part of a bacteriostatic agent, 0.05 to 15 parts of a buffering agent and the balance of normal saline, and the pH value of the eye drops is 5.0 to 7.0. Experiments show that L-ergothioneine can prevent and reverse denaturation of crystalline lens protein, the prepared eye drops containing L-ergothioneine can prevent and reduce opacity of crystalline lens protein, and the prevention and treatment effects on cataract are better than those of existing eye drops.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to nitrogen hydrochloride # imgabs0 # stine eye drops and a preparation process thereof, the nitrogen hydrochloride # imgabs0 # stine eye drops comprise 0.05% of nitrogen hydrochloride # imgabs1 # stine, 0.2-0.3% of hydroxypropyl methylcellulose, 0.1-0.2% of edetate disodium, 0.12-0.15% of an isoosmotic adjusting agent, 0.04-0.07% of a preservative and 0.005-0.0075% of choline aromatic folic acid; the nitrogen hydrochloride # imgabs2 # stine eye drops prepared by the preparation method disclosed by the invention have the advantages that the adsorption of nitrogen hydrochloride # imgabs3 # stine on a low-density polyethylene bottle is well inhibited under the condition of visible light, and the reduction of the concentration of nitrogen hydrochloride # imgabs4 # stine in the eye drops is remarkably prevented, so that the medication safety is improved. Besides, the added cholinofolic acid and hydroxypropyl methylcellulose have small irritation to eyes under a specific ratio, and can also have a large enough contact angle with the eyes of rabbits at high temperature, so that the retention property of the eye drops on the eyes can be improved, and the drug effect can be favorably exerted.

The present invention relates to the technical field of eye drops, and specifically discloses a kind of wetting boric acid eye drops. The present invention also discloses a preparation method of the above-mentioned wetting boric acid eye drops, boric acid, chlorhexidine gluconate solution, and calcium disodium edetate are added to water, and stirred at 60-70°C to obtain a boric acid complex; sodium hyaluronate and sodium alginate are added to water and stirred, and hypromellose is added, and stirred at 30-40°C to obtain a hypromellose complex; soy lecithin, cholesterol, and ethylparaben are added to chloroform and stirred to obtain phase A; collagen and carboxymethyl chitosan are added to citric acid aqueous solution and stirred to obtain phase B; phase A is added to phase B under stirring, ultrasonic treatment, 50-60°C vacuum rotary evaporation to remove chloroform, citric acid aqueous solution is added for hydration, ultrasonic treatment, and filtration to obtain liposomes; boric acid complex, hypromellose complex, and liposomes are mixed evenly, and the pH value of the adjustment system is 6.5-7.5.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a method for detecting the content of carbomer in eye drops. The method comprises the following steps: by adopting a two-time washing and centrifugal separation mode, controlling the washing and centrifugal times, centrifugal conditions and washing volume, separating carbomer and brinzolamide from other auxiliary materials in the brinzolamide eye drops, obtaining the weights of carbomer and brinzolamide by adopting a drying and weighing mode, subtracting the weight of brinzolamide, and calculating the content of the auxiliary materials in the brinzolamide eye drops. And calculating to obtain the carbomer content in the sample. The method is suitable for detecting the carbomer content in the carbomer-containing brinzolamide eye drops, and is simple and convenient to operate, efficient, accurate and low in cost.

The invention discloses traditional Chinese medicine suspension eye drops and a preparation method thereof, and the traditional Chinese medicine suspension eye drops are prepared from the following raw materials in parts by weight: 1-3 parts of a traditional Chinese medicine composition, 4-7 parts of hydroxypropyl-beta-cyclodextrin, 0.5-2 parts of microcrystalline cellulose-sodium carboxymethyl cellulose and auxiliary materials. The traditional Chinese medicine suspension eye drops provided by the invention abandon a traditional eye ointment form, are directly dropped for use, are convenient to use, have good stability and dispersity, and are excellent in use curative effect and medication experience; on the basis of keeping the clinical efficacy of the Marcher eight-treasure ancient prescription, secondary development and research are scientifically carried out, so that the Marcher eight-treasure ancient prescription plays a greater clinical treatment role, and has a wider market development prospect.

The invention provides pet tear stain eye drops containing haematococcus pluvialis extract, the pH value of the eye drops is 6.8-7.2, the osmotic pressure is 280-320 mOsm / kg, the viscosity is 3-8 mPa.s (25 DEG C), and the eye drops comprise the following components in percentage by mass: 0.05-0.5% of haematococcus pluvialis astaxanthin extract (based on the astaxanthin content being greater than or equal to 5%), 0.05-0.5% of a pH regulator (based on the astaxanthin content being greater than or equal to 5%), and the balance of water. 1%-3% of an anti-inflammatory plant compound; 0.5%-1.2% of an isoosmotic adjusting agent; 0.2%-0.8% of a nano carrier stabilizer; 0.01%-0.1% of a pH buffer agent; compared with the prior art, the invention has the following beneficial effects: the corneal permeability of the astaxanthin is increased to 82% (measured by a Franz diffusion cell) through PLGA coating, and is increased by 5.5 times compared with the corneal permeability of the astaxanthin in a free state (15%); natural tocopherol is reserved through supercritical CO2 extraction (the content of the natural tocopherol is larger than or equal to 0.5% through HPLC detection), and the retention rate of the astaxanthin stored at 40 DEG C for 90 days is larger than or equal to 90% through Calendula quercitrin inhibits the expression of IL-6 (enzyme-linked immunosorbent assay (ELISA) detection is reduced by 76%), and chamomile bisabolol blocks a COX-2 pathway.

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug / cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

The eye drops are prepared from the following components in percentage by mass: 0.1 percent to 0.5 percent of chondroitin sulfate, 0.06 percent to 0.3 percent of sericin protein nanoparticles containing astaxanthin, 0.1 percent to 0.3 percent of sodium hyaluronate, 0.05 percent to 0.1 percent of vitamin E, 0.9 percent to 1.0 percent of sodium chloride, 0.05 percent to 0.1 percent of poloxamer, 0.01 percent to 0.1 percent of EDTA (Ethylene Diamine Tetraacetic Acid), a phosphate buffer solution and the balance of water, wherein the particle size of the sericin nano-particles containing the astaxanthin is 50 to 300 nm; the phosphate buffer solution is used for adjusting the pH value of the eye drops to 6.8-7.9. The eye drops can effectively relieve the dry eye symptom, provide long-time wetting and protection, reduce eye inflammation and oxidative stress, remarkably improve the dry eye symptom and are high in use safety.

The invention discloses a composition and a preparation method of a single-dose vitamin B12 eye drop without a bacteriostatic agent, and the single-dose vitamin B12 eye drop without the bacteriostatic agent is prepared from vitamin B12, a buffering agent, sodium hyaluronate, edetate disodium and water for injection. According to the vitamin B12 eye drops and the preparation method thereof disclosed by the invention, the vitamin B12 eye drops are produced by adopting a totally-closed sterile filling process, and a disposable single-dose packaging container is arranged, so that the sterility of medicines is ensured, and meanwhile, the use safety, the operation convenience index and the safety performance are improved.

The invention discloses a self-emulsifying nervonic acid eye drop, which is prepared from the following raw material components in percentage by mass: 1 to 10 weight percent of nervonic acid, 30 to 60 weight percent of oil phase, 20 to 40 weight percent of surfactant and 10 to 20 weight percent of co-emulsifier, the oil phase is at least one of sunflower seed oil, squalane, olive oil and castor oil. According to the invention, the oil phase rich in unsaturated fatty acid is adopted, so that the eye cream has good solubility to nervonic acid, is mild and low-sensitive, can soften the cuticle of eyes and reduce the permeation resistance of nervonic acid, and is suitable for sensitive periocular skin. The prepared self-emulsifying nervonic acid eye drops overcome the defect that nervonic acid is almost insoluble in water, and compared with water-based eye drops, the self-emulsifying nervonic acid eye drops have the advantage that the drug loading capacity and the stability are obviously improved.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses timolol maleate eye drops and a preparation method thereof. The timolol maleate eye drops provided by the invention are prepared from timolol maleate, glycine, trehalose, disodium hydrogen phosphate and sodium dihydrogen phosphate. According to the timolol maleate eye drops, the components of the timolol maleate eye drops are reasonably designed, and glycine and trehalose are added into the timolol maleate eye drops, so that degradation of active components of the timolol maleate eye drops is also reduced while the types and the dosage of auxiliary materials are reduced, and the eye drops have the advantages that the eye drops are safe and reliable; the stability of the timolol maleate eye drops placed for a long time is obviously improved, and the medication safety of the timolol maleate eye drops is ensured.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to pemirolast potassium eye drops and a preparation method thereof. The pemirolast potassium eye drops are composed of pemirolast potassium, hydroxypropyl ethyl cellulose, an osmotic pressure regulator, disodium hydrogen phosphate, a pH regulator and water for injection, and the prescription does not contain a bacteriostatic agent, so that the irritation of the eye drops to eye tissue cells is reduced; the pemirolast potassium eye drops provided by the invention are simple in prescription process, stable and controllable in quality and high in safety.

1. Name of the designed product: packing box (sodium hyaluronate eye drops). 2. Use of the designed product: the designed product is mainly used for packing of medicines. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: design 1 perspective view. 5. Design 1 is designated as the basic design.

The invention relates to compound herba houttuyniae eye drops as well as a preparation method and application of the compound herba houttuyniae eye drops. Comprising the following preparation raw materials in percentage by mass: 1-6% of a herba houttuyniae extracting solution, 1-5% of an aglaia odorata extracting solution, 1-2% of a gelidium amansii extracting solution, 0.1-0.3% of acyclovir, 0.1-0.3% of tobramycin, 0.01-0.1% of dexamethasone sodium phosphate, 0.1-1% of sodium hyaluronate, 0.1-3% of glycerol and 88-93% of purified water. According to the compound herba houttuyniae eye drops prepared by the preparation method disclosed by the invention, the herba houttuyniae extracting solution, the aglaia odorata extracting solution, the gelidium amansii extracting solution, the acyclovir, the tobramycin and the dexamethasone sodium phosphate are combined for use, so that the compound herba houttuyniae eye drops have a relatively good curative effect on pets suffering from bacterium and virus mixed infection type conjunctivitis / keratitis; the compound herba houttuyniae eye drops are good in high-temperature-resistant storage stability and good in curative effect, the problem of frequent administration can be reduced, and the compound herba houttuyniae eye drops are more convenient to use and store.

The invention belongs to the technical field of eye drops, and relates to a cell-penetrating peptide modified nano cerium oxide eye drop and a preparation method and application thereof.The nano cerium oxide eye drop contains water-soluble nano cerium oxide, and the surface of the water-soluble nano cerium oxide is provided with phospholipid polyethylene glycol maleimide coupled annular cell-penetrating peptide; the surface of the water-soluble nano cerium oxide has positive potential; wherein the water-soluble nano cerium oxide contains trivalent cerium and tetravalent cerium. According to the invention, modification of the amphiphilic cell-penetrating peptide is added on the surface of the water-soluble nano cerium oxide, so that the surface of the water-soluble nano cerium oxide has relatively high positive potential, and the affinity of the cell-penetrating peptide to cell membranes is added, so that the retention time of the ocular surface is effectively prolonged, and the permeation effect of anterior segment of the eye is improved; the anterior chamber drug concentration for local eye drop treatment is increased, the stability of the nanoparticles in common media is guaranteed, and the nanoparticles can be kept stable and not aggregated in artificial tears, PBS and pure water for more than 30 days.

The invention relates to a single-dose pilocarpine hydrochloride eye drop composition and a preparation method thereof, and belongs to the technical field of medicine preparation. The composition comprises a buffering agent, an osmotic pressure regulator and a solvent, and the composition does not contain a bacteriostatic agent. By using reasonable process preparation parameters, the prepared finished product is good in stability, the process parameters are simple and easy to operate, and the method has good application prospects and market value.

1. Name of the product of this design: Packaging box (polyvinyl alcohol eye drops). 2. Purpose of this design product: This design product is used for polyvinyl alcohol eye drops. 3. The key design point of this design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the design points: expanded view.

The utility model discloses eye drop medicine bottle cleaning equipment which comprises a mounting plate, a power source arranged near the mounting plate, a pushing piece connected with the power source, a pushing plate arranged on the mounting plate in a sliding mode, a clamping piece arranged below the pushing plate and a containing opening formed in the pushing plate. The liquid medicine bottle is placed in the placing opening, and the water spraying holes are formed in the mounting plate; the liquid medicine bottle is fixed in the containing opening through the clamping piece, the power source pushes the pushing plate through the pushing piece, and the liquid medicine bottle is moved to the water spraying hole to be cleaned. According to the eye drop medicine bottle cleaning equipment, batch cleaning of medicine bottles is achieved, the production efficiency is improved, the cleaning effect is ensured, and the pollution risk caused by manual intervention is reduced.

The invention discloses difunctional nano drug-loaded eye drops for xerophthalmia and a preparation method of the difunctional nano drug-loaded eye drops, and belongs to the field of pharmaceutical preparation technologies and ophthalmology pharmacy. The core of the invention is to construct a composite nanoparticle which has a core-shell structure and has long-acting adhesion lubrication and targeted control drug release functions. The preparation method comprises the following steps: firstly, encapsulating a hydrophobic immunosuppressant such as cyclosporine A in a biodegradable pad polymer matrix such as polylactic acid-glycolic acid copolymer (PLGA) by an emulsification-solvent evaporation method to form a drug-loaded polymer nano core; through the exquisite integrated design of the structure and the function, collaborative targeted therapy of two core pathological links of'tear film instability 'and'immune inflammation' of xerophthalmia is achieved, the bioavailability of the medicine is remarkably improved, the medication frequency and eye irritation are reduced, and the curative effect of xerophthalmia is improved. A more efficient and safer administration scheme with better patient compliance is provided for clinical treatment of xerophthalmia.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

The embodiment of the invention provides high-stability eye drops and a preparation method thereof.The method comprises the steps that traditional Chinese medicinal materials are cleaned, dried in the sun and extracted to obtain corresponding extracts; the preparation method comprises the following steps: carrying out ultrasonic breaking on a water-phase dispersion liquid of nanofibers to form nanofibers smaller than 40 nanometers, adding disodium hydrogen phosphate to adjust the pH value, standing at the temperature of lower than 0 DEG C for 1-5 hours, taking out, carrying out ultrasonic stirring at room temperature, and repeating the steps for many times to obtain a fiber liquid; adding the extract into the fiber liquid, uniformly stirring, freezing and thawing at-5 to-15 DEG C, putting at room temperature, adding a mixed alcohol solution, stirring, adding into a sterile buffer solution, and sterilizing to obtain the eye drops. The eye drops provided by the invention have excellent stability and can exert the efficacy for a long time.

The present application relates to the technical field of medicine, in particular to a kind of siRNA eye drop for penetrating mucus barrier and cell barrier and preparation method thereof.Innovative development side chain guanidino group-containing polydisulfide delivery carrier is used in the present application, through the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on mucin, tear film retention and efficient penetration are realized, and cationic polydisulfide is quickly adsorbed on the surface of negative charged cell membrane by electrostatic interaction, the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on cell membrane is used, and endocytosis is used to quickly penetrate tight junction cell layer.

The invention relates to perillaseed oil nanoemulsion eye drops as well as a preparation method and application thereof, and belongs to the technical field of medicines. The perillaseed oil nanoemulsion eye drops comprise the following raw material components in parts by mass: 1-20 parts of perillaseed oil, 0.1-10 parts of an emulsifier, 0-10 parts of a co-emulsifier, 0.05-3 parts of a metal ion chelating agent and 1-5 parts of an osmotic pressure regulator. By adding the metal ion chelating agent and controlling the preheating temperature, the problem that perillaseed oil is easy to oxidize is solved. According to the perilla oil nanoemulsion eye drops, the perilla oil serves as an effective component to exert the drug effect and also serves as an oil phase, meanwhile, the particle size of the nanoemulsion is accurately controlled by adjusting the variety of the co-emulsifier, and the safety and stability of the perilla oil nanoemulsion eye drops are further improved. The perillaseed oil eye drops provided by the invention can effectively relieve the symptoms of xerophthalmia and asthenopia, and a new medication choice is provided for treating xerophthalmia and myopia.